Russian state plans to take measures to solve problem of counterfeit drugs

5 October 2021

The illegal drug market in Russia is estimated to be worth 15–20 billion roubles ($205-274 million), according to a recent study, conducted by analysts at RNC Pharma, one of Russia’s leading pharma analytics agencies.

The drug labeling system, which was launched in Russia in 2020, was supposed to solve this problem, however, most experts believe it will not completely solve the problem, which remains pressing for Russia and its pharmaceutical sector.

Recently, the Russian police conducted controlled purchase operations in some Moscow pharmacies, as a result of which large volumes of counterfeit drugs were detected.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK